

Jeffrey A Cohen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2034013/jeffrey-a-cohen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

19,917
citations

46
h-index

141
g-index

160
ext. papers

23,885
ext. citations

9
avg, IF

6.47
L-index

#	Paper	IF	Citations
149	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
148	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018 , 17, 162-173	24.1	2419
147	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
146	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
145	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1819-28	40	834
144	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	40	827
143	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 383-90	5	428
142	A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. <i>Nature</i> , 1989 , 339, 230-1	50.4	404
141	Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 69, 759-77	9.4	286
140	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 263-81	5	203
139	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology, The</i> , 2011 , 10, 520-9	24.1	178
138	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126	6.5	175
137	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. <i>Lancet Neurology, The</i> , 2012 , 11, 467-76	24.1	174
136	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet, The</i> , 2017 , 389, 1357-1366	40	174
135	Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 704-710	5	163
134	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116	6.5	139
133	Vision and vision-related outcome measures in multiple sclerosis. <i>Brain</i> , 2015 , 138, 11-27	11.2	136

132	Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. <i>Archives of Neurology</i> , 2001 , 58, 961-7		136
131	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
130	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2016 , 15, 373-81	24.1	118
129	Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. <i>Neurology</i> , 2014 , 82, 674-80	6.5	113
128	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
127	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
126	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033	24.1	98
125	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1009-1020	24.1	96
124	Mesenchymal stem cell transplantation in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013 , 333, 43-9	3.2	94
123	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. <i>Neurology</i> , 2015 , 84, 784-93	6.5	93
122	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 282-93	5	91
121	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 494-504	4	91
120	Combination therapy in multiple sclerosis. <i>Lancet Neurology</i> , 2010 , 9, 299-308	24.1	91
119	Sphingosine 1-phosphate receptor modulators in multiple sclerosis. <i>CNS Drugs</i> , 2015 , 29, 565-75	6.7	89
118	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
117	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013 , 260, 2023-32	5.5	72
116	Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017 , 14, 859-873	6.4	68
115	The potential for vigabatrin-induced intramyelinic edema in humans. <i>Epilepsia</i> , 2000 , 41, 148-57	6.4	63

114	Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1781-1790	5	63
113	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 540-5	9.4	60
112	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 501-511	5	58
111	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 629-38	4	58
110	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105	5	56
109	Multiple sclerosis: new insights in pathogenesis and novel therapeutics. <i>Annual Review of Medicine</i> , 2012 , 63, 389-404	17.4	55
108	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. <i>Lancet Neurology</i> , 2020 , 19, 336-347	24.1	54
107	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 1506-1514	6.9	53
106	Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 69, 75-82	9.4	53
105	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1446-1453	6.5	51
104	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2015 , 72, 1433-41	17.2	50
103	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 845-854	4.7	46
102	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617	5	46
101	Early tolerability and safety of fingolimod in clinical practice. <i>Journal of the Neurological Sciences</i> , 2012 , 323, 167-72	3.2	42
100	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. <i>Journal of the American College of Radiology</i> , 2017 , 14, 371-379.e1	3.5	39
99	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992	6.5	38
98	The 2013 clinical course descriptors for multiple sclerosis: A clarification. <i>Neurology</i> , 2020 , 94, 1088-1092	6.5	37
97	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1469-1484	5	37

96	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 44-52	4	36
95	Fingolimod therapy for multiple sclerosis. <i>Seminars in Neurology</i> , 2013 , 33, 37-44	3.2	35
94	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1704-13	5	34
93	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1157-1162	5	34
92	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1163-1171	3.4	34
91	Multiple sclerosis symptom management. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 1213-22	4.3	32
90	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 23-37	5	32
89	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419878324	6.6	31
88	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. <i>Neurology</i> , 2019 , 93, e1921-e1931	6.5	31
87	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 332-415	5	30
86	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1437-1445	6.5	30
85	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1627-1635	5	27
84	Experience with fingolimod in clinical practice. <i>International Journal of Neuroscience</i> , 2015 , 125, 678-85	2	25
83	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
82	Safety of monoclonal antibodies for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 89-100	4.1	24
81	Emerging therapies for relapsing multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 821-8		24
80	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - AuthorsTreply. <i>Lancet Neurology</i> , 2018 , 17, 499-500	24.1	22
79	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β 1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472	6.5	21

78	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. <i>Neurology: Clinical Practice</i> , 2018 , 8, 292-301	1.7	19
77	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055-2173	17.1	5485
76	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 81-92	9.4	18
75	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1909-1917	5	17
74	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 1423-1437	2.9	17
73	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <i>Immunotherapy</i> , 2014 , 6, 249-258	5.8	16
72	Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. <i>Lancet, The</i> , 2021 , 398, 1184-1194	4.0	16
71	Emerging oral therapies in multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 381-386	4.6	15
70	Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). <i>Expert Review of Clinical Pharmacology</i> , 2011 , 4, 567-70	3.8	14
69	Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. <i>Neurology</i> , 2014 , 83, 192-4	6.5	13
68	CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. <i>Experimental Neurology</i> , 2017 , 295, 222-232	5.7	12
67	Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descent. <i>American Journal of Medical Genetics Part A</i> , 1999 , 86, 194-6		12
66	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 997-1013	4.3	11
65	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102454	4	11
64	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020 , 7,	9.1	11
63	Clemastine fumarate for promotion of optic nerve remyelination. <i>Lancet, The</i> , 2017 , 390, 2421-2422	4.0	10
62	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. <i>Contemporary Clinical Trials</i> , 2020 , 95, 106009	2.3	9
61	Handbook of Multiple Sclerosis 2012 ,		9

60	Movement disorders in early MS and related diseases: A prospective observational study. <i>Neurology: Clinical Practice</i> , 2019 , 9, 24-31	1.7	9
59	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319856035	2	8
58	Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. <i>Lancet Neurology, The</i> , 2011 , 10, 4-5	24.1	8
57	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1581-1589	5	8
56	How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2008 , 4, 588-9		7
55	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101525	4	7
54	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 601-609	5	7
53	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. <i>Neurology: Clinical Practice</i> , 2020 , 10, 222-231	1.7	6
52	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318765288 ²		6
51	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. <i>Journal of the Neurological Sciences</i> , 2019 , 407, 116498	3.2	6
50	Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations. <i>EBioMedicine</i> , 2018 , 29, 5-6	8.8	5
49	Fingolimod. <i>Neurology: Clinical Practice</i> , 2011 , 1, 61-65	1.7	5
48	The future of multiple sclerosis treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 277 Suppl 1, S55-63.	3.2	5
47	Newer versus older treatments for relapsing-remitting multiple sclerosis. <i>Drug Safety</i> , 1996 , 14, 121-30	5.1	5
46	Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials. <i>Nature Reviews Neurology</i> , 2016 , 12, 253-4	15	5
45	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319891744	2	5
44	Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	4
43	Integrating multiple sclerosis guidelines into practice. <i>Lancet Neurology, The</i> , 2018 , 17, 658-660	24.1	4

42	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101335	4	4
41	Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211057110	2	1
40	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. <i>Neurology</i> , 2020 , 94, 273-275	6.5	4
39	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319887198	2	4
38	The emergence of follow-on disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1560-1565	5	3
37	Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies. <i>Nature Reviews Neurology</i> , 2015 , 11, 316-7	15	3
36	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
35	Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 9, 129-134	4	3
34	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
33	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. <i>CNS Drugs</i> , 2021 , 35, 985-997	6.7	3
32	Continuing Clinical Research During Shelter-in-Place. <i>Annals of Neurology</i> , 2020 , 88, 658-660	9.4	2
31	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
30	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2219-2231	5	2
29	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217318819245	2	2
28	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021 , 28, 3722-3730	6	2
27	Measurement of CNS atrophy128-149		1
26	Appraisal of the multiple sclerosis functional composite. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 335-41	4.3	1
25	Women's Health in Multiple Sclerosis: A Scoping Review.. <i>Frontiers in Neurology</i> , 2021 , 12, 812147	4.1	1

24	Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. <i>Neurology: Clinical Practice</i> , 10.1212/CPJ.0000000000001149	1.7	1
23	MRI findings in blinded trials should be available to treating physicians - No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 814-815	5	1
22	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1749-1759	5	1
21	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. <i>Journal of Neurology</i> , 2021, 1	5.5	1
20	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.. <i>Multiple Sclerosis Journal</i> , 2022, 13524585221078825	5	1
19	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. <i>Neurology: Clinical Practice</i> , 2021, 11, 352-357	1.7	0
18	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. <i>Multiple Sclerosis Journal</i> , 2021, 13524585211035333	5	0
17	Perspectives and experiences with COVID-19 vaccines in people with MS.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 20552173221085242	2	0
16	Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?. <i>Frontiers in Neurology</i> , 2022, 13, 844873	4.1	0
15	Measures of neurological impairment and disability in multiple sclerosis56-64		
14	Assessment of neuropsychological function in multiple sclerosis65-78		
13	The use of MRI in multiple sclerosis clinical trials198-212		
12	Interferon beta to treat multiple sclerosis300-314		
11	Treatment for patients with primary progressive multiple sclerosis604-613		
10	Management of pediatric multiple sclerosis632-644		
9	Management of medical comorbidities in patients with multiple sclerosis714-723		
8	Fingolimod to treat multiple sclerosis370-386		
7	Aspects of multiple sclerosis that relate to experimental therapeutics1-11		

- 6 Ligand Binding to the Cell-Surface Receptor for Reovirus Type 3 Alters Schwann Cell Growth and Function. *Annals of the New York Academy of Sciences*, **1990**, 605, 412-415 6.5
- 5 Truncal ataxia presumably due to malignant spinal cord compression. *Annals of Neurology*, **1987**, 21, 511-524 6.4
- 4 Long-term ocrelizumab in progressive multiple sclerosis. *Lancet Neurology*, **2020**, 19, 966-968 24.1
- 3 Multiple Sclerosis Wellness Shared Medical Appointment Model: A Pilot Study. *International Journal of MS Care*, **2021**, 23, 229-233 2.3
- 2 Evolution of the Diagnostic Criteria in Multiple Sclerosis **2021**, 75-87
- 1 Disease-modifying therapy for multiple sclerosis in clinical practice 583-603